These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 10359669

  • 21. Alpha-synuclein, Abeta and Alzheimer's disease.
    Wirths O, Bayer TA.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):103-8. PubMed ID: 12551731
    [Abstract] [Full Text] [Related]

  • 22. Multiple ligand interaction of alpha-synuclein produced various forms of protein aggregates in the presence of Abeta25-35, copper, and eosin.
    Kim YS, Lee D, Lee EK, Sung JY, Chung KC, Kim J, Paik SR.
    Brain Res; 2001 Jul 20; 908(1):93-8. PubMed ID: 11457435
    [Abstract] [Full Text] [Related]

  • 23. Incubation with Cu(II) and Zn(II) salts enhances MALDI-TOF mass spectra of amyloid-beta and α-synuclein toward in vivo analysis.
    Kelley AR, Colley ME, Perry G, Bach SBH.
    J Mass Spectrom; 2018 Feb 20; 53(2):162-171. PubMed ID: 29111606
    [Abstract] [Full Text] [Related]

  • 24. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.
    Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E.
    J Mol Neurosci; 2002 Feb 20; 19(1-2):63-9. PubMed ID: 12212795
    [Abstract] [Full Text] [Related]

  • 25. Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases.
    Sung JY, Park SM, Lee CH, Um JW, Lee HJ, Kim J, Oh YJ, Lee ST, Paik SR, Chung KC.
    J Biol Chem; 2005 Jul 01; 280(26):25216-24. PubMed ID: 15863497
    [Abstract] [Full Text] [Related]

  • 26. alpha-Synuclein exhibits competitive interaction between calmodulin and synthetic membranes.
    Lee D, Lee SY, Lee EN, Chang CS, Paik SR.
    J Neurochem; 2002 Sep 01; 82(5):1007-17. PubMed ID: 12358748
    [Abstract] [Full Text] [Related]

  • 27. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils.
    Bodles AM, Guthrie DJ, Harriott P, Campbell P, Irvine GB.
    Eur J Biochem; 2000 Apr 01; 267(8):2186-94. PubMed ID: 10759841
    [Abstract] [Full Text] [Related]

  • 28. Properties of NACP/alpha-synuclein and its role in Alzheimer's disease.
    Iwai A.
    Biochim Biophys Acta; 2000 Jul 26; 1502(1):95-109. PubMed ID: 10899435
    [Abstract] [Full Text] [Related]

  • 29. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.
    Uversky VN, Li J, Fink AL.
    J Biol Chem; 2001 Nov 23; 276(47):44284-96. PubMed ID: 11553618
    [Abstract] [Full Text] [Related]

  • 30. Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases.
    Tabner BJ, Turnbull S, El-Agnaf O, Allsop D.
    Curr Top Med Chem; 2001 Dec 23; 1(6):507-17. PubMed ID: 11895127
    [Abstract] [Full Text] [Related]

  • 31. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.
    Kessler JC, Rochet JC, Lansbury PT.
    Biochemistry; 2003 Jan 28; 42(3):672-8. PubMed ID: 12534279
    [Abstract] [Full Text] [Related]

  • 32. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
    Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC.
    Neurobiol Aging; 2005 Jan 28; 26(8):1183-92. PubMed ID: 15917102
    [Abstract] [Full Text] [Related]

  • 33. Aggregation of alpha-synuclein induced by the Cu,Zn-superoxide dismutase and hydrogen peroxide system.
    Kim KS, Choi SY, Kwon HY, Won MH, Kang TC, Kang JH.
    Free Radic Biol Med; 2002 Mar 15; 32(6):544-50. PubMed ID: 11958955
    [Abstract] [Full Text] [Related]

  • 34. Binding of copper (II) ion to an Alzheimer's tau peptide as revealed by MALDI-TOF MS, CD, and NMR.
    Ma QF, Li YM, Du JT, Kanazawa K, Nemoto T, Nakanishi H, Zhao YF.
    Biopolymers; 2005 Oct 05; 79(2):74-85. PubMed ID: 15986501
    [Abstract] [Full Text] [Related]

  • 35. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation.
    Li HT, Du HN, Tang L, Hu J, Hu HY.
    Biopolymers; 2002 Aug 05; 64(4):221-6. PubMed ID: 12115139
    [Abstract] [Full Text] [Related]

  • 36. The synuclein family.
    Lavedan C.
    Genome Res; 1998 Sep 05; 8(9):871-80. PubMed ID: 9750188
    [Abstract] [Full Text] [Related]

  • 37. Dequalinium-induced protofibril formation of alpha-synuclein.
    Lee CH, Kim HJ, Lee JH, Cho HJ, Kim J, Chung KC, Jung S, Paik SR.
    J Biol Chem; 2006 Feb 10; 281(6):3463-72. PubMed ID: 16330551
    [Abstract] [Full Text] [Related]

  • 38. Alpha-synuclein oligomerization: a role for lipids?
    Welch K, Yuan J.
    Trends Neurosci; 2003 Oct 10; 26(10):517-9. PubMed ID: 14522142
    [Abstract] [Full Text] [Related]

  • 39. Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease.
    Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, Griesinger C, Jovin TM, Fernández CO.
    Proc Natl Acad Sci U S A; 2005 Mar 22; 102(12):4294-9. PubMed ID: 15767574
    [Abstract] [Full Text] [Related]

  • 40. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA.
    Acta Neuropathol; 2003 Sep 22; 106(3):191-201. PubMed ID: 12845452
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.